Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910689 · ClinicalTrials.gov registry record · Phase 4
Drug and Non-Drug Treatment Of Severe Migraine
A Phase 4 study, sponsored by Ohio University.
- Completed
- Registry status
- Phase 4
- Development phase
- 232
- Enrollment target
NCT00910689: Completed Phase 4 study, sponsored by Ohio University.
NCT00910689 is a Phase 4 study that has completed, run by Ohio University. The registered enrollment target is 232 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00910689, a Phase 4 study, has completed, sponsored by Ohio University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 232 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of preventive medication, behavior migraine management or the combination of preventive medication and behavior migraine management improves the outcome of optimal acute therapy for frequent migraines.
Primary Outcome
Change in number of migraine episodes(with 24 hours pain free period required between episodes)per 30 days from OAT run-in (Month 1) to Month 10.Obtained from daily electronic diary.
Interventions
- DRUG Placebo control
- DRUG Propranolol or nadolol
- BEHAVIORAL Behavioral Migraine Management (BMM)
- DRUG Optimal Acute Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2001-07 |
| Est. Completion | 2005-11 |
| Phase | Phase 4 |
What the finished NCT00910689 record still lists
NCT00910689 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo control is the first listed.
NCT00910689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00910689 about?
NCT00910689 is a clinical study titled "Drug and Non-Drug Treatment Of Severe Migraine". The purpose of this study is to determine if the addition of preventive medication, behavior migraine management or the combination of preventive medication and behavior migraine management improves the outcome of optimal acute therapy for frequent migraines.
What is the current status of trial NCT00910689?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 232 participants. The study started on 2001-07. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00910689?
The interventions under investigation include: Placebo control (DRUG), Propranolol or nadolol (DRUG), Behavioral Migraine Management (BMM) (BEHAVIORAL), Optimal Acute Therapy (DRUG).
Who is sponsoring clinical trial NCT00910689?
This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00910689's enrollment target sits among peer trials
232 370th of 2000 higher than 1,631 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia